Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns
Outsourcing Pharma
SEPTEMBER 26, 2024
The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.
Let's personalize your content